|
Compound class:
Synthetic organic
Comment: Losudesivir is the INN for an adenosine analogue that is intended as a coronavirus antiviral agent. The structure was obtained from WHO INN Proposed List 135 (July 2026). It represents an orally bioavailable RdRp inhibitor known by the codes SHEN26 and ATV014 that exhibits broad-spectrum activity against multiple coronaviruses [3-5]. Structurally, losudesivir is a cyclohexane carboxylate prodrug of the parent compound and active metabolite of remdesivir, GS-441524. Mechanistically RdRp inhibitors disrupt viral nucleic acid synthesis and thereby replication.
|
|
|||||||||||||||||||||||||||||||||||
For advanced searching click here to open chemical structure editor